跳至主要内容
临床试验/NCT00067951
NCT00067951已完成3 期

An Open-label Trial to Evaluate the Safety and Efficacy of Fixed Dose Rosiglitazone/Metformin Combination Therapy in Poorly-controlled Subjects With Type 2 Diabetes Mellitus

GlaxoSmithKline95 个研究点 分布在 2 个国家目标入组 190 人开始时间: 2003年10月17日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
190
试验地点
95
主要终点
Hemoglobin A1c (HbA1c) reduction after 24 weeks of treatment.

研究概览

简要总结

The purpose of this research study is to determine if a new investigational diabetes drug is safe and effective in treating people who have Type II diabetes mellitus with very high HbA1c or FPG (fasting plasma glucose) levels. The HbA1c test, also called the hemoglobin A1c test or glycated hemoglobin test, is a measurement of the average amount of sugar in the blood over the last 2 to 3 months. FPG is a test that measures the amount of sugar in the blood after an 8 hour fast.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Laboratory result for HbA1c >11% or FPG >270mg/dL
  • Clinical diagnosis of Type II diabetes
  • Prior treatment with diet and/or exercise alone, or less than 15 days of prior treatment with an oral anti-diabetic medication or insulin.

排除标准

  • Women who are pregnant

结局指标

主要结局

Hemoglobin A1c (HbA1c) reduction after 24 weeks of treatment.

次要结局

  • Change in FPG, insulin,C-peptide, insulin sensitivity,beta cell function, free fatty acids, lipids. Change in weight, vital signs, clinical laboratory tests, and adverse experiences.

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (95)

Loading locations...

相似试验

A Study To Evaluate The Safety And Efficacy Of An... | 临床试验